+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Contrast sensitivity in patients with cataract submitted to chronic treatment with bendazac lysine eye drops



Contrast sensitivity in patients with cataract submitted to chronic treatment with bendazac lysine eye drops



Annali di Ottalmologia e Clinica Oculistica 114(10): 1001-1020



Administration 3 times a day of Bendazac-lysine eye drops (Bendalina) causes at least in cortical cataracts, an improvement in visual functions due to a decrease of light scattering phenomena since it is easier to detect with blue targets than with red ones. The improvement for blue targets is not as obvious in subcapsular cataracts which however after treatment present a better peak sensitivity for red targets. In subcapsular cataracts the location of the lens opacity is such that impairs visual acuity more so than an increase in optical density. In nuclear cataracts an imporvement is detectable for an higher spatial frequency and for red targets. This could depend on some effect of bendazac-lysine on the retina.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 007156995

Download citation: RISBibTeXText


Related references

Clinical trial of bendazac lysine eye drops in the medical treatment of cataract. Bollettino di Oculistica 68(5): 823-834, 1989

Psychophysical and electrofunctional contrast sensitivity in cataractous patients treated with bendazac-lysine salt. Documenta Ophthalmologica. Advances in Ophthalmology 76(3): 285-296, 1990

Critical evaluation of bendazac lysine salt in the treatment of cataract. Bollettino di Oculistica 63(11-12): 1271-1282, 1984

Treatment of early cortical cataract experience with bendazac lysine salt. Prensa Medica Argentina 72(11): 380-383, 1985

Clinical evaluation of topical bendazac lysine in treatment of senile cataract. Bollettino di Oculistica 67(1): 25-30, 1988

Medical treatment of senile cataract: clinical investigation of bendazac-lysine using objective and subjective methods. Graefe's Archive for Clinical and Experimental Ophthalmology 228(2): 105-111, 1990

Controlled clinical evaluation of bendazac lysine in senile cataract a multicenter study analysis of the effects of 6 months treatment. Bollettino di Oculistica 64(1-2): 71-88, 1985

Characterization of a novel process-related impurity in commercial bendazac lysine eye drops by LC-ESI-QTOF/MS/MS and NMR. Journal of Pharmaceutical and Biomedical Analysis 107: 437-443, 2015

Bendazac Lysine in Selected Types of Human Senile Cataract. Ophthalmic Research 21(3): 141-154, 1989

Basic data supporting the use of the l-lysine salt of bendazac in cataract. International Journal of Tissue Reactions 5(2): 217-225, 1983

0.25 percent bendazac lysine eye drops efficacy in keratoconjunctivitis sicca a double blind randomized clinical cytological trial. Bollettino di Oculistica 70(3): 541-546, 1991

Senile and presenile cataract therapy with bendazac lysine a clinical evaluation. Bollettino di Oculistica 65(4): 671-684, 1986

Effects of bendazac L-lysine salt on X-ray-induced cataract in the rabbit lens. Experimental Eye Research 42(2): 167-175, 1986

New methods for studying lens opacities results of a double blind pilot study on the effect of bendazac lysine in senile cataract. Annali di Ottalmologia e Clinica Oculistica 111(12): 1085-1102, 1985

Contrast sensitivity for colored gratings in the follow up of patients suffering from cataract during medical treatment. Annali di Ottalmologia e Clinica Oculistica 113(6): 525-532, 1987